Actively Recruiting
Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
Led by Jiangxi Provincial Cancer Hospital · Updated on 2025-07-25
109
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Nasopharyngeal carcinoma (NPC) is a malignant tumor that develops in the nasopharyngeal mucosal epithelium. Due to the disease itself and the impact of anti-tumor therapy, malnutrition has become a common clinical complication in patients with NPC, among which NPC patients receiving concurrent chemoradiotherapy are one of the groups with the highest incidence of malnutrition, and malnutrition seriously affects the prognosis of NPC patients. Nutritional management throughout the course has a positive impact on the prognosis and life management of NPC patients. As an immune-enhancing oral nutritional preparation, it is helpful to maintain the weight and immune function of patients with nasopharyngeal carcinoma during concurrent chemoradiotherapy, reduce the degree of treatment-related side effects during concurrent chemoradiotherapy for nasopharyngeal carcinoma, and delay the occurrence of acute side effects. The purpose of this study was to investigate the effect of rapid rapid rapid improvement of patients' immune status during concurrent chemoradiotherapy, and to further evaluate its impact on patients' weight, prognosis, treatment-related toxic side effects, and quality of life. In this study, 109 patients with nasopharyngeal carcinoma who received concurrent chemoradiotherapy in our hospital are planned to be included, and all patients in this group will be given oral tachyphin at a standard dose from the first day of radiotherapy. The nutritional immune status of the patient was assessed at different points during the treatment period.
CONDITIONS
Official Title
Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with nasopharyngeal carcinoma confirmed by histopathology
- Clinical stage II to IVa
- Receiving concurrent chemoradiotherapy as part of treatment
- Age 18 years or older, male or female
- PG-SGA score between 0 and 8 before radiotherapy
- KPS score 60 or higher or ECOG score 3 or lower
- Able to receive nutritional supplementation orally or enterally
- Signed informed consent according to hospital policies
- Serum hemoglobin 90 g/L or higher
- Platelet count 100 x 10^9/L or higher
- Absolute neutrophil count 1.5 x 10^9/L or higher
- Serum creatinine less than or equal to 1.25 times the upper limit of normal or creatinine clearance 60 mL/min or higher
- Serum bilirubin less than or equal to 1.5 times the upper limit of normal
- AST (SGOT) and ALT (SGPT) less than or equal to 2.5 times the upper limit of normal
- Alkaline phosphatase less than or equal to 5 times the upper limit of normal
You will not qualify if you...
- Presence of a second primary tumor
- Not receiving concurrent chemoradiotherapy
- Having diabetes mellitus or a history of severe endocrine and metabolic diseases
- Allergy to oral nutritional meal replacements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
Actively Recruiting
Research Team
Y
Yong Su, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here